Log in using OpenID

Antibacterial Drugs Market Is Expected To Have The Highest Growth Rate During The Forecast Period 2026

The Global Antibacterial Drugs Market size was valued at US$ 43,791.2 million in 2017, and is expected to exhibit a CAGR of 1.4% over the forecast period (2018 – 2026).
Antibacterial Drugs Market To Witness Widespread
Expansion During 2026
Antibacterial Drugs Market - Global Forecast to 2026, by Drug class (Beta
lactams, Quinolones, Macrolides, Tetracycline, Aminoglycoside, Sulfonamide,
Phenicols, and Others), by Route of Administration (Oral, Topical, Parenteral,
and Others), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies,
and Online Pharmacies) and by Region (North America, Latin America, Europe,
Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity
Analysis, 2018-2026
The Global Antibacterial Drugs Market size was valued at US$ 43,791.2 million in 2017, and is
expected to exhibit a CAGR of 1.4% over the forecast period (2018 – 2026).
Antibacterial drugs are used in treatment or prohibition of bacterial infections caused due to various
factors such as climatic changes, unhygienic lifestyle specially in emerging economies and others.
Major challenge associated with antibacterial drugs is resistance of bacteria towards it. Significant
studies are carried out to develop new antibacterial drugs to combat these problems.
Market Dynamics
Increasing prevalence of infectious diseases is a major factor driving antibacterial drugs market growth.
According to World Health Organization (WHO), September 2018, annually around 11 million to 21
million cases of typhoid fever are reported worldwide. Moreover, growing geriatric population
susceptible to high risk of bacterial infection, majorly caused due to age related changes in
immunology is expected to boost the market growth. The Current Opinion in Microbiology Journal
2016, stated Lower respiratory tract infection (Pneumonia), as the most common cause of infection
disease in older patients in the U.S. and estimated it as 6 leading cause of death in the U.S.
However, price control of antibacterial drugs, genetic mutation in aging population, and decrease in
financial incentives has distracted the focus of pharmaceutical companies from research and
development of antibacterial drugs. In September 2016, AstraZeneca announced an agreement with
Pfizer to sell the development and commercialization rights to its late-stage small molecule antibiotics
business as AstaZeneca does not find antibiotic research as major area for development in their
Increasing population and high incidences of infectious diseases in North America are expected to
bolster the market growth
North America holds dominant position in the global antibacterial drugs market, owing to rising
population base susceptible to infectious diseases and higher incidences of infectious diseases such as
tuberculosis and others. According to the Centers for Disease Control and Prevention (CDC), in 2017,
an estimated 9,105 patients were diagnosed with tuberculosis in the U.S.
Ask For Sample Copy Of This Business Research Report :
Moreover, key players in the market are focused on receiving the U.S. Food and Drug Administration
(FDA) approval for novel products to treat patients diagnosed with infectious diseases. For instance, in
February 2019, Novartis received the U.S. Food and Drug Administration (FDA) approval for Egaten,
used for the treatment of Fascioliasis caused by Fasciola hepatica infection.
Key Players
Major players operating in the global antibacterial drugs market include Novartis AG, Allergan, Bristol
Myers Squibb Company, AstraZeneca, Johnson and Johnson, Merck & Co., Inc., GlaxoSmithKline Plc.
(GSK), Sanofi SA, Bayer AG, and Pfizer Inc.
Detailed Segmentation:
•Global Antibacterial Drugs Market, By Drug class:
•Beta lactams
•Quinolones Macrolides
•Global Antibacterial Drugs Market, By Route of Administration:
•Global Antibacterial Drugs Market, By Distribution Channel:
•Hospital Pharmacies
•Retail Pharmacies
•Online Pharmacies
Increasing incidences of infectious diseases is expected to propel growth of the antibacterial drugs
Antibacterial drugs are used in treatment of infection caused by various bacteria such as Escherichia
coli, Klebsiella pneumonia, and others. Moreover, increasing incidences of infectious diseases such as
tuberculosis, hepatitis B, leprosy, typhoid, malaria, HIV/AIDS and others is expected to drive the
market growth. According to the World Health Organization (WHO) November 2018 factsheet, an
estimated 219 million people were diagnosed by malaria in 2017, in 19 countries.
Moreover, initiatives by government concerned to antibacterial resistance is expected to propel market
growth over the forecast period. For instance, in May 2018, the UK government announced fund of
US$ 34 million to fight against antimicrobial resistance (AMR). This funding will be distributed to the
4 projects such as Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator of US$ 23
million, Global Antibiotic Research and Development Partnership invested US$ 1 million, and US$ 5
million for two project such as bilateral partnership with Argentina and Foundation for Innovative New
About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready
syndicated research reports, custom market analysis, consulting services, and competitive analysis
through various recommendations related to emerging market trends, technologies, and potential
absolute dollar opportunity.
Contact Us:
Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Tel: +1–206–701–6702
Email: [email protected]
ravikiran303   documents Email
Health and Medicine
File Size
383 KB
Report inappropriate content